Crosstalk between hesperetin and miR-486-5p in triple-negative breast cancer (TNBC): An approach towards precision medicine

Abstract

without intermediate cell foci. Two monoclonal cases showed histologically ambiguous border between HCC and CC components with more intermingled pattern than biclonal cases. Conclusions: We compared genetic compositions of HCC and CC components and matched clonality with histologic feature in cHCC-CC using targeted sequencing. Two (50%) of four cases had different clones between HCC and CC components with more distinguished histologic features than monoclonal cases. Considering such heterogeneity, partly sequencing is recommended for cHCC-CC, especially in those who have histologically distinguished HCC and CC components regardless of the presence of intermediate component.Legal entity responsible for the study: Nara Yoon. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.85P The role of topoisomerase II-a (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer

Chemotherapeutic potential of hesperetin for cancer treatment, with mechanistic insights: A comprehensive review

“…In MDA-MB-231 breast cancer cells, HSP reduces glucose uptake by down-regulating glucose transporter 1 (GLUT1) and 4 (GLUT4), inhibits insulin receptor-beta subunit (IR-beta) phosphorylation and Akt, leading to suppressed cell proliferation in response to 5-100 μM concentration [63]. Abdallah and his colleagues found that HSP can also increase the expression of miR-486-5P that is responsible for reducing cell viability, clonogenicity, and metastatic potential in similar cell lines [64]. According to Chandrika et al, 10-500 μM of HSP causes apoptosis and reduces cell growth in MDA-MB-231 and SKBR3 breast cancer cells.…”